Status:
UNKNOWN
Radiotherapy in Hepatocellular Carcinomas After Hepatectomy With Narrow Margin (<1 cm) or Portal Vein Thrombosis
Lead Sponsor:
Guangxi Medical University
Conditions:
HepatoCellular Carcinoma
Eligibility:
All Genders
Brief Summary
Hepatocellular carcinoma (HCC) is one of ten leading cancer types worldwide and also in Asia, but the five-year relative survival rate is relatively quite low1-3. As a common complication of HCC, port...
Eligibility Criteria
Inclusion
- HCC with no preoperative RT
- resectable lesion that could be completely removed, at the same time retaining a sufficient residual liver tissue to maintain adequate function
- compensated cirrhosis or no cirrhosis; Child-Pugh A
- ECOG Performance Status of 0 or 1.
- Patients who had undergone transarterial chemoembolization (TACE) were eligible for enrollment in the study, provided this form of therapy ended at least 4 weeks before study entry
Exclusion
- unresectable hepatocellular carcinoma patients
- Hepatocellular carcinoma without portal vein tumor thrombus
- Hepatectomy without narrow margin(more than 1cm)
- presence of distant metastasis
- palliative resection with tumor residual
- non-HCC confirmed by postoperative pathology
Key Trial Info
Start Date :
January 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT02309788
Start Date
January 1 2016
Last Update
January 26 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
TaoBai
Nanning, Guangxi, China, 530000